{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:45:06Z","timestamp":1791895506688,"version":"4.3.4"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,12,25]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a chronic, progressive, disabling neurodegenerative disorder. Deep brain stimulation (DBS) surgery is a highly effective and beneficial therapy for advanced PD, but its substantial cost limits accessibility. This study aimed to evaluate the cost\u2013utility and budget impact of rechargeable and non-rechargeable DBS compared with standard pharmacotherapy alone in patients with advanced PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cost\u2013utility analysis using a Markov model with a 6-month cycle length and a 20-year time horizon. Costs were valued in 2025 Thai Baht, and both costs and outcomes were discounted at 3% per year. The model consisted of six health states based on the Modified Hoehn &amp; Yahr scale. The primary outcome was the incremental cost-effectiveness ratio (ICER) expressed as cost per quality-adjusted life-year (QALY) gained. Secondary outcomes included total costs, life-years, QALYs and a 5-year budget impact from the government perspective. Deterministic and probabilistic sensitivity analyses were conducted to assess parameter uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Medication alone produced 5.80 QALYs, compared with 7.38 QALYs for both rechargeable and non-rechargeable DBS, yielding 1.57 incremental QALYs. Rechargeable DBS resulted in an incremental cost of THB506 720 (US$15\u2009678), corresponding to an ICER of THB321 940 (US$9958) per QALY. While non-rechargeable DBS resulted in an incremental cost of THB639 454 (US$19\u2009785), corresponding to an ICER of THB406 272 (US$12\u2009567) per QALY. Probabilistic analysis produced similar values (ICERs of THB293\u2009354\u2013THB350\u2009761 per QALY). All ICERs exceeded Thailand\u2019s willingness-to-pay threshold of THB160 000 (US$4950) per QALY. The projected 5-year budget impact was THB60.9\u2013THB69.0\u2009million (US$1.9\u2013US$2.1\u2009million) per year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DBS for patients with advanced PD is not currently cost-effective within Thailand\u2019s national healthcare system. Supported by the actionable evidence in this study, strategic pricing and policy changes will enable equitable access to therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001464","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:35:12Z","timestamp":1768887312000},"page":"e001464","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Deep brain stimulation for Parkinson\u2019s disease in Thailand: cost, utility and policy implications for universal health coverage"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8183-348X","authenticated-orcid":false,"given":"Saharat","family":"Aungsumart","sequence":"first","affiliation":[{"name":"Department of Neurology, Neurological Institute of Thailand, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atittan","family":"Songpattanasilp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurological Institute of Thailand, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0256-164X","authenticated-orcid":false,"given":"Surachet","family":"Rujirussawarawong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurological Institute of Thailand, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawarat","family":"Ounmuang","sequence":"additional","affiliation":[{"name":"Chulabhorn Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praewchompoo","family":"Sathirapanya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurological Institute of Thailand, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natlada","family":"Limotai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurological Institute of Thailand, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026051208151559000_8.1.e001464.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61393-3"},{"key":"2026051208151559000_8.1.e001464.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101834"},{"key":"2026051208151559000_8.1.e001464.3","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A"},{"key":"2026051208151559000_8.1.e001464.4","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13549"},{"key":"2026051208151559000_8.1.e001464.5","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson\u2019s Disease in 204 Countries\/Territories From 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front Public Health"},{"key":"2026051208151559000_8.1.e001464.6","doi-asserted-by":"publisher","DOI":"10.1159\/000334440"},{"key":"2026051208151559000_8.1.e001464.7","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.260","article-title":"Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues","volume":"68","author":"Bronstein","year":"2011","journal-title":"Arch Neurol"},{"key":"2026051208151559000_8.1.e001464.8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/mds.28599","article-title":"Translating Evidence to Advanced Parkinson\u2019s Disease Patients: A Systematic Review and Meta-Analysis","volume":"36","author":"Nijhuis","year":"2021","journal-title":"Mov Disord"},{"key":"2026051208151559000_8.1.e001464.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-022-09540-9"},{"key":"2026051208151559000_8.1.e001464.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70093-4"},{"key":"2026051208151559000_8.1.e001464.11","first-page":"529","article-title":"SW2-year outcomes of subthalamic deep brain stimulation for idiopathic Parkinson\u2019s disease","volume":"93","author":"Nunta-Aree","year":"2010","journal-title":"J Med Assoc Thai"},{"key":"2026051208151559000_8.1.e001464.12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372"},{"key":"2026051208151559000_8.1.e001464.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060281"},{"key":"2026051208151559000_8.1.e001464.14","doi-asserted-by":"crossref","DOI":"10.1186\/s40064-016-3665-4","article-title":"Thailand\u2019s universal coverage scheme and its impact on health-seeking behavior","volume":"5","author":"Paek","year":"2016","journal-title":"Springerplus"},{"key":"2026051208151559000_8.1.e001464.15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.wneu.2015.11.062","article-title":"Cost-Effectiveness Analysis of Deep Brain Stimulation in Patients with Parkinson\u2019s Disease in Japan","volume":"89","author":"Kawamoto","year":"2016","journal-title":"World Neurosurg"},{"key":"2026051208151559000_8.1.e001464.16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22875"},{"key":"2026051208151559000_8.1.e001464.17","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20993"},{"key":"2026051208151559000_8.1.e001464.18","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G454"},{"key":"2026051208151559000_8.1.e001464.19","unstructured":"HITAP . The health intervention and technology assessment program foundation. Thailand\u2019s Life Table 2014; 2014. Available: https:\/\/www.hitap.net\/wp-content\/uploads\/2014\/06\/LifeTable2014.xlsx"},{"key":"2026051208151559000_8.1.e001464.20","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2018.1494574"},{"key":"2026051208151559000_8.1.e001464.21","unstructured":"Vacharin P . Working group on the guidelines for health technology assessment in thailand. In: Guidelines for Health Technology Assessment in Thailand. 2nd edn. Nonthaburi, Thailand, 2013."},{"key":"2026051208151559000_8.1.e001464.22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/ner.12474","article-title":"Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson\u2019s Disease in the United States","volume":"19","author":"Pietzsch","year":"2016","journal-title":"Neuromodulation"},{"key":"2026051208151559000_8.1.e001464.23","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/j.wneu.2020.02.150","article-title":"Cost-Effectiveness Analysis of Deep Brain Stimulation for Parkinson Disease in Taiwan","volume":"138","author":"Fann","year":"2020","journal-title":"World Neurosurg"},{"key":"2026051208151559000_8.1.e001464.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa000827"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:15:39Z","timestamp":1778598939000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,19]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2025-001464"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001464","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}